Revolution Operating Cash Flow Sales Ratio from 2010 to 2024

RVMDW Stock   0.36  0.04  11.18%   
Revolution Medicines, Operating Cash Flow Sales Ratio yearly trend continues to be fairly stable with very little volatility. Operating Cash Flow Sales Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Revolution Medicines, Operating Cash Flow Sales Ratio regression line of quarterly data had mean square error of  57.72 and geometric mean of  0.39. View All Fundamentals
 
Operating Cash Flow Sales Ratio  
First Reported
2010-12-31
Previous Quarter
(30.27)
Current Value
(28.76)
Quarterly Volatility
10.20693123
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Revolution Medicines, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revolution Medicines,'s main balance sheet or income statement drivers, such as Net Interest Income of 49.5 M, Interest Income of 49.9 M or Interest Expense of 287.9 K, as well as many indicators such as Price To Sales Ratio of 294, Dividend Yield of 0.0 or PTB Ratio of 1.69. Revolution financial statements analysis is a perfect complement when working with Revolution Medicines, Valuation or Volatility modules.
  
Check out the analysis of Revolution Medicines, Correlation against competitors.

Latest Revolution Medicines,'s Operating Cash Flow Sales Ratio Growth Pattern

Below is the plot of the Operating Cash Flow Sales Ratio of Revolution Medicines, Warrant over the last few years. It is Revolution Medicines,'s Operating Cash Flow Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revolution Medicines,'s overall financial position and show how it may be relating to other accounts over time.
Operating Cash Flow Sales Ratio10 Years Trend
Slightly volatile
   Operating Cash Flow Sales Ratio   
       Timeline  

Revolution Operating Cash Flow Sales Ratio Regression Statistics

Arithmetic Mean(4.88)
Geometric Mean0.39
Coefficient Of Variation(209.27)
Mean Deviation6.78
Median0.06
Standard Deviation10.21
Sample Variance104.18
Range30.3341
R-Value(0.70)
Mean Square Error57.72
R-Squared0.49
Significance0
Slope(1.59)
Total Sum of Squares1,459

Revolution Operating Cash Flow Sales Ratio History

2024 -28.76
2023 -30.27
2022 -6.34
2021 -5.01
2020 -2.33
2019 -0.99

About Revolution Medicines, Financial Statements

Revolution Medicines, investors use historical fundamental indicators, such as Revolution Medicines,'s Operating Cash Flow Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revolution Medicines,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cash Flow Sales Ratio(30.27)(28.76)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Revolution Stock Analysis

When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.